Stock Identified as Having More Than Doubled in 2025: Is It Worth an Investment?
Tempus AI Sees Significant Growth and Analyst Approval
Tempus AI, a healthcare technology company based in Illinois, has reported impressive financial results for its second quarter of fiscal 2025. The company, founded in 2015, specialises in genomic profiling, AI-powered diagnostics, and data services across various diseases.
The second-quarter gross profit surged to $195 million, reflecting a 160% year-over-year increase. This growth was driven by improved cost management and a strategic shift towards higher-margin products. Genomics was the star performer, with a 115.3% year-over-year increase in revenue.
Tempus AI's adjusted loss per share came in at $0.22, an improvement from the $0.63 loss reported in the same quarter last year. Adjusted EBITDA narrowed from a negative $31.2 million in Q2 2024 to a negative $5.6 million in Q2 2025. The company has projected an adjusted EBITDA of $5 million for the year, representing a $110 million improvement over last year.
The strong financial performance has not gone unnoticed by analysts. Among 14 analysts covering the stock, five call it a "Strong Buy," two lean towards a "Moderate Buy," and the remaining seven have issued a "Hold" rating. H.C. Wainwright, in particular, raised its price target on Tempus AI to $98, keeping a "Buy" rating in place. Currently, 7 out of 13 analysts have an optimistic "buy" rating on Tempus AI, with a consensus price target averaging $70.17. The lowest target is $52.00, and the highest is $98.00, indicating a moderate buy sentiment overall.
Tempus AI's stock jumped over 13% on Sept. 11, 2025, following the release of these financial results. The company also strengthened its balance sheet by completing an upsized $750 million 0.75% convertible senior notes offering. Cash and marketable securities ended the quarter at $293 million, roughly $70 million higher than the prior quarter.
In other news, the U.S. Food and Drug Administration granted clearance for an upgraded version of Tempus Pixel, an AI-powered cardiac imaging platform of Tempus AI. This development further cements Tempus AI's position as a leader in AI-driven healthcare innovation.
With a market capitalization of roughly $15 billion, Tempus AI continues to attract investor attention by leveraging advanced data and AI to support doctors, researchers, and drug developers. The company's strong financial performance, coupled with its innovative approach, positions it well for future growth.
Read also:
- Trump and Xi speak over the phone, according to China's confirmation.
- Linde Wins Major Engineering Design Contract for Equinor's Low Carbon Hydrogen Project at H2H Saltend, Progressing Towards a Greener Future
- Economic Growth of Nitric Acid for Electronic Applications Anticipated to Reach 5.8% by 2034
- Stock markets in Asia experience a surge following a record-breaking rally in U.S. stocks, fueled by optimism towards potential interest rate reductions.
